RYTARY Drug Patent Profile

When do Rytary patents expire, and when can generic versions of Rytary launch?

Rytary is a drug marketed by Impax and is included in one NDA. There are eight patents protecting this drug and two Paragraph IV challenges.

This drug has twenty-five patent family members in twelve countries.

The generic ingredient in RYTARY is carbidopa; levodopa. There are eighteen drug master file entries for this compound. Thirty-eight suppliers are listed for this compound. Additional details are available on the carbidopa; levodopa profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Rytary

A generic version of RYTARY was approved as carbidopa; levodopa by DR REDDYS LABS SA on August 28^th, 1992.

Summary for RYTARY

International Patents:	25
US Patents:	8
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	3
Raw Ingredient (Bulk) Api Vendors:	7
Clinical Trials:	2
Patent Applications:	2,231
Drug Prices:	Drug price information for RYTARY
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for RYTARY
What excipients (inactive ingredients) are in RYTARY?	RYTARY excipients list
DailyMed Link:	RYTARY at DailyMed

See drug prices for RYTARY

See drug sales revenues for RYTARY

Recent Clinical Trials for RYTARY

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
The Cleveland Clinic	PHASE4
Amneal Pharmaceuticals, LLC	PHASE4
National Institutes of Health (NIH)	Phase 2

See all RYTARY clinical trials

Pharmacology for RYTARY

Drug Class

Aromatic Amino Acid

Paragraph IV (Patent) Challenges for RYTARY

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
RYTARY	Extended-release Capsules	carbidopa; levodopa	23.75 mg/95 mg, 36.25 mg/145 mg, 48.75 mg/195 mg	203312	1	2015-06-24
RYTARY	Extended-release Capsules	carbidopa; levodopa	61.25 mg/245 mg	203312	1	2015-06-10

US Patents and Regulatory Information for RYTARY

RYTARY is protected by fifteen US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Impax	RYTARY	carbidopa; levodopa	CAPSULE, EXTENDED RELEASE;ORAL	203312-003	Jan 7, 2015		RX	Yes	No	9,901,640		Y
Impax	RYTARY	carbidopa; levodopa	CAPSULE, EXTENDED RELEASE;ORAL	203312-004	Jan 7, 2015		RX	Yes	Yes	9,089,608		Y
Impax	RYTARY	carbidopa; levodopa	CAPSULE, EXTENDED RELEASE;ORAL	203312-003	Jan 7, 2015		RX	Yes	No	9,089,608		Y
Impax	RYTARY	carbidopa; levodopa	CAPSULE, EXTENDED RELEASE;ORAL	203312-004	Jan 7, 2015		RX	Yes	Yes	9,089,607		Y

Expired US Patents for RYTARY

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Impax	RYTARY	carbidopa; levodopa	CAPSULE, EXTENDED RELEASE;ORAL	203312-001	Jan 7, 2015	7,094,427
Impax	RYTARY	carbidopa; levodopa	CAPSULE, EXTENDED RELEASE;ORAL	203312-002	Jan 7, 2015	7,094,427
Impax	RYTARY	carbidopa; levodopa	CAPSULE, EXTENDED RELEASE;ORAL	203312-003	Jan 7, 2015	7,094,427
Impax	RYTARY	carbidopa; levodopa	CAPSULE, EXTENDED RELEASE;ORAL	203312-004	Jan 7, 2015	7,094,427

EU/EMA Drug Approvals for RYTARY

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Amneal Pharma Europe Ltd	Numient	levodopa, carbidopa	EMEA/H/C/002611Symptomatic treatment of adult patients with Parkinson’s disease	Withdrawn	no	no	no	2015-11-19

International Patents for RYTARY

When does loss-of-exclusivity occur for RYTARY?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Canada

China

European Patent Office

Israel

Japan

Mexico

New Zealand

South Africa

South Korea

Spain

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering RYTARY around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	2003247409	COMBINATION IMMEDIATE RELEASE CONTROLLED RELEASE LEVODOPA/CARBIDOPA DOSAGE FORMS
Canada	2486859	ASSOCIATION DE FORMES POSOLOGIQUES DE LEVODOPA/CARBIDOPA A LIBERATION IMMEDIATE ET CONTROLEE (COMBINATION IMMEDIATE RELEASE CONTROLLED RELEASE LEVODOPA/CARBIDOPA DOSAGE FORMS)
European Patent Office	1507518	ASSOCIATION DE FORMES POSOLOGIQUES DE LEVODOPA/CARBIDOPA A LIBERATION IMMEDIATE ET CONTROLEE (COMBINATION IMMEDIATE RELEASE CONTROLLED RELEASE LEVODOPA/CARBIDOPA DOSAGE FORMS)
European Patent Office	2921170	Combinaison à libération immédiate de lévodopa à libération contrôlée/formes posologiques de carbidopa (Combination immediate release controlled release levodopa/carbidopa dosage forms)

Supplementary Protection Certificates for RYTARY

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
3209302	2390502-9	Sweden		PRODUCT NAME: FOSLEVODOPA/FOSCARBIDOPA; NAT. REG. NO/DATE: MTNR 62386 20220912; FIRST REG.: AT 141371 20220826

RYTARY (carbidopa/levodopa extended-release capsules) Market Dynamics and Financial Trajectory: exclusivity, competitive risk, payer pressure, and revenue outlook

Last updated: July 21, 2026

RYTARY revenue trajectory is shaped by (1) Parkinson’s disease (PD) treatment substitution within levodopa regimens, (2) generics and authorized generics timing risk to carbidopa/levodopa ER competitors, (3) payer step edits and prior authorization tied to dosing economics, and (4) litigation and exclusivity that determine near-term brand resilience.

What is Rytary’s current commercial position in Parkinson’s disease and what drives demand?

Direct answer: RYTARY competes inside the levodopa-based PD backbone market against immediate-release carbidopa/levodopa and extended-release formulations, with share anchored by patient-specific dosing flexibility (multiple strengths) and clinical perceptions around symptom control. Demand is constrained by payer controls on drug cost per day and by therapeutic interchange risk.

How does Rytary differentiate vs levodopa competitors?

• Dosing flexibility: Multiple capsule strengths support individualized total daily dose titration without switching to a different dosage form for small adjustments.
• Formulation behavior: RYTARY uses an extended-release platform intended to reduce “off” time relative to immediate-release levodopa and smooth plasma exposure. That matters to payers only when it translates to lower rescue medication use or improved persistence.
• Substitution pressure: In most formularies, payers evaluate cost per therapeutic day and whether prescribers can manage with alternatives (generic immediate-release levodopa or other ER options).

What payer and channel factors determine Rytary persistence?

• Step therapy and prior authorization: Common in PD formularies when plan designs aim to start with lower-cost levodopa regimens.
• Preferred tier placement: Brands that secure preferred status typically gain share via lower access friction.
• Real-world adherence dynamics: If patients experience reduced “off” time and can keep stable dosing, persistence improves and improves net revenue durability. If adverse effects or dosing complexity increases discontinuation, the commercial slope flattens.

What is the Rytary financial trajectory and how has the revenue curve evolved by market segment?

Direct answer: The financial trajectory for RYTARY generally follows a branded specialty pattern: steady growth after launch driven by uptake in neurologist prescribing, then plateau pressure from therapeutic substitution and payer tightening, with any acceleration tied to milestone-driven payer and access wins or post-competition re-anchoring.

Revenue drivers that push the curve up

• Neurology channel penetration: RYTARY growth historically correlates with neurologist adoption and formulary inclusion.
• Patient transfer from immediate-release carbidopa/levodopa: Conversions expand the initial base when prescribers switch patients for symptom control.
• Persistence and dose optimization: Sustained use after titration supports repeat prescription volume.

Revenue headwinds that flatten the curve

• Therapeutic interchange: If payers require switch to lower-cost levodopa products, volume shifts.
• Pricing pressure: Contracting and rebates increase over time when competitors gain negotiating leverage.
• Competition from other ER levodopa formulations: Brand substitutes dilute incremental share.

What margins and net-to-gross dynamics typically look like for PD brands

• High rebate intensity risk: Specialty brands often see net price erosion when formulary access is contested by generics or lower-priced authorized entrants.
• Cost-per-day negotiation: Contracts increasingly anchor on total daily dosing cost, not list price.

Which patents protect Rytary and how strong is the IP estate for long-term brand exclusivity?

Direct answer: RYTARY’s ability to sustain premium pricing relies on its patent estate covering formulation and composition and any method-of-use or manufacturing improvements. A complete, numbered patent-to-product mapping requires Orange Book listings, which are the controlling source for expiration timing and exclusivity coverage.

What patent estate categories usually matter for Rytary commercial protection?

• Formulation patents: Protect capsule composition and extended-release particle/technology approaches.
• Method-of-manufacture patents: Protect processing steps that preserve extended-release behavior.
• Method-of-use patents: Protect dosing schedules or therapeutic use that differentiates from earlier levodopa regimens.
• Combination or component patents: Protect specific carbidopa/levodopa delivery systems rather than just the actives.

How to read Rytary exclusivity vs patent expiration

• Regulatory exclusivity (data exclusivity, patent term adjustments, and any FDA exclusivity grants) defines a floor for competition timing.
• Patent expiration defines the ceiling for Paragraph IV generic entry or other “at-risk” launches.
• Later-expiring formulation/manufacturing patents tend to drive the risk profile even after initial exclusivity ends.

When does Rytary lose exclusivity and what generic entry risks exist?

Direct answer: Generic entry risk is tied to (1) Orange Book patent expiration and (2) whether any listed patents are subject to Paragraph IV challenges or have been carved out via settlement. Without a product-specific Orange Book table for RYTARY, the only actionable statement is that the entry window opens only once all relevant listed patents have expired or been cleared.

How Paragraph IV challenges would impact launch economics

• At-risk launch timing: Filing triggers litigation and can delay entry via automatic stays (under the Hatch-Waxman framework) if statutory requirements are met.
• Settlement-driven launch: If a settlement grants a future launch date, net volume losses can be front-loaded on market access terms (formularies switch preferences).

What “authorized generic” risk means for Rytary

• Even if branded protection holds, an authorized generic can compress RYTARY net pricing and share by offering near-therapeutic alternatives at lower acquisition cost.

What patent litigation affects Rytary and what settlements shaped the competitive landscape?

Direct answer: Litigation risk is central to timing of generic and substitution threats. The actionable analysis depends on case dockets and Orange Book patent mapping, including:

• case numbers,
• asserted patents,
• parties (brand, generic challengers),
• court outcomes,
• settlement launch dates.

Without the underlying docket and Orange Book patent list, no defensible, numbered litigation timeline can be produced.

What is the Orange Book status of Rytary and how many listed patents cover the product?

Direct answer: Orange Book status determines the practical expiration schedule and litigation exposure. A complete “how many patents” and “expiration dates” table requires the Orange Book listing for RYTARY’s NDA and all listed patents.

What you should extract from Orange Book for a competitive risk model

• NDA number for RYTARY
• Listed patents with patent numbers
• Patent expiration dates (including regulatory adjustments)
• Exclusivity codes (if any)
• Dosage form scope (capsules strengths, extended release)
• Patent type (composition, method of use, manufacturing)

How does Rytary compare with carbidopa/levodopa immediate-release and other ER formulations on price and access?

Direct answer: Competition in PD levodopa regimens is less about clinical differentiation alone and more about payer economics per treated day, adherence, and formulary status.

What tends to drive payer switching from Rytary

• Total daily cost comparison: if competing products meet the plan’s per-day threshold.
• Coverage policy: whether RYTARY is preferred or non-preferred.
• Prior authorization friction: if criteria are strict and prescribers struggle to meet them.
• Budget impact: even a modest share shift can drive meaningful budget changes for large payer groups.

What tends to protect Rytary share

• High prescriber belief in symptom control translating into persistence.
• Access wins: lower PA rates, continued formulary presence, and favorable rebate terms.
• Patient stability after switching to RYTARY that limits voluntary back-switching.

Is Rytary exposed to biosimilar-style replacement risk, and why or why not?

Direct answer: Biosimilar replacement is not applicable to RYTARY because it is a small-molecule product (carbidopa/levodopa), not a biologic. The competitive threat comes from generics, authorized generics, and other small-molecule levodopa ER technologies.

What geographic coverage matters most for Rytary revenue and where is it most exposed?

Direct answer: RYTARY’s revenue exposure is typically largest in the US due to the US patent and generic entry framework (Hatch-Waxman). Ex-US markets face different data protection and patent enforcement timelines under local law, but the controlling launch timing risk in most investment models is US regulatory status plus patent expiry.

How to model region-specific risk

• US: driven by Orange Book status, patent expiration, Paragraph IV challenges, and litigation timelines.
• EU/UK: driven by local patent coverage, SPCs (if applicable), and national enforcement.
• Canada/Japan: driven by local regulatory approvals and patent linkage regimes (where applicable).

Key commercial scenarios that affect Rytary’s next 24–48 months

Direct answer: Market outcomes cluster into three scenarios: (1) continued branded resilience with limited erosion, (2) gradual share compression from step edits and preferred-tier shifts, or (3) accelerated volume and net price decline if patent clearance triggers generic entry or authorized generic expansion.

Scenario 1: Branded resilience through access management

• Net price holds via contracting.
• Persistence remains stable.
• Competitors expand use mostly among newly treated patients rather than converting existing RYTARY users.

Scenario 2: Net price erosion without immediate generic entry

• Formulary re-tiering increases access friction.
• Share moves to lower-cost alternatives with similar dosing coverage.

Scenario 3: Patent clearance and generic/authorized generic entry

• Faster volume loss and sharp net price compression.
• Higher rebate demands to defend share may not fully offset volume loss.

Key Takeaways

• RYTARY’s financial trajectory is primarily a function of US patent-linked competition timing and payer access economics inside levodopa-based PD therapy.
• Therapeutic interchange and formulary pressure drive revenue plateau and net price erosion even before formal generic entry.
• Full precision on exclusivity end dates, number of Orange Book patents, and Paragraph IV/settlement timelines requires the RYTARY Orange Book patent list and litigation docket mapping; these determine the practical risk window for generic entry.

FAQs

1) What patents protect Rytary’s extended-release capsule formulation?
Answer: Formulation and manufacturing patents typically protect the extended-release performance of RYTARY; the definitive set is the RYTARY Orange Book patent list for the relevant NDA.

2) When does Rytary lose exclusivity in the US?
Answer: The exclusivity and patent expiration timeline is governed by the latest-expiring listed Orange Book patents associated with the RYTARY NDA.

3) What generic entry risks exist for Rytary if a Paragraph IV is filed?
Answer: A Paragraph IV can trigger an automatic litigation stay and delay entry; settlement can also fix a launch date, controlling near-term market disruption.

4) How does Rytary pricing compare on a cost-per-day basis versus immediate-release carbidopa/levodopa?
Answer: Payer-driven net cost-per-day comparisons and formulary status determine whether RYTARY remains preferred; list price is secondary to rebates, discounts, and coverage criteria.

5) Is Rytary exposed to biosimilar competition?
Answer: No. RYTARY is a small-molecule drug (carbidopa/levodopa), so the main replacement risk is from generics or other small-molecule ER products, not biosimilars.

References

1. FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. (RYTARY listing). https://www.accessdata.fda.gov/scripts/cder/daf/ (accessed 2026-07-21)

DrugChatter Q&A for RYTARY

Rytary sales information covered for us european?
Patent infringement cases with rytary?
Is rytary going generoc anytime soon?
When does the patent run out on rytary?
Who sponsored the trials for rytary?